Abstract
Fifty-three women with clinical evidence of adenocarcinoma of the breast were studied with technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg. An overall per lesion efficacy of 83.5% sensitivity and 97.7% positive predictive value was obtained. Efficacy appears higher in lesions restricted to the breast and local regional disease than systemic metastases. For the 2 mg dose the breast/local regional disease efficacy was 90% sensitivity and 90.2% positive predictive value. The biodistribution of this MAb was best represented by a two-compartment model with a distribution-phase half-life of 4.0±1.4 h, followed by an elimination-phase half-life of 39.6±6.6 h. In all six patients studied, the crticial organ was the kidney, with a mean radiation absorbed dose of 37±6.9 mGy/GBq. The accuracy of this imaging technique allows the development of diagnostic strategies for the routine use of the compound in patients with breast cancer.
Similar content being viewed by others
References
Kelsey JL, Gammon MD. The epidemiology of breast cancer.CA Cancer J Clin 1991; 41: 146–165.
Kopans DB.Breast imaging. Philadelphia: Lippincott, 1989.
Kopans DB. The positive predictive value of mammography.AJR 1992; 158: 521–526.
Schmidt JG. The epidemiology of mass breast cancer screening — a plea for a valid measure of benefit.J Clin Epidemiol 1990; 43: 215–225.
Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy patients.J Clin Oncol 1993; 11: 1536–1544.
Rubin E. Critical pathways in the analysis of breast masses.RadioGraphics 1995; 15: 925–927.
McEwan AJB, MacLean GD, Hopper HR, et al. MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with99mTc and with111In.Nucl Med Commun 1992; 13: 11–19.
Longenecker BM, Willans DJ, MacLean GD, et al. Monoclonal antibodies and synthetic tumor associated glycoconjugates to study the expression of Thomsen-Friedenreich (TF)-like and Tn-like antigens on human cancers.J Natl Cancer Inst 1987; 78: 489–496.
Samuel J, Noujaim AA, MacLean GD, et al. Analysis of human tumor associated Thomsen-Friedenreich antigen.Cancer Res 1990; 50: 4801–4808.
Harris CC, Greer KL, Jaszczak RJ, et al. 99m-Te attenuation coefficients in water-filled phantoms determined with gamma cameras.Med Phys 1984; 11: 687.
Bailey DL, Hutton BF, Walker PJ. Improved SPECT using simultaneous emission and transmission tomography.J Nucl Med 1987; 28: 844.
Ediss C, Tam YK. An interactive program for determining areas bounded by drug concentration curves using Lagrange interpolation.J Pharmacol Toxicol Methods 1995; 34: 165–168.
Cloutier SR, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder.Health Phys 1973; 25: 147–161.
Loevinger R, Budinger TF, Watson EE.MIRD primer for absorbed dose calculations. New York, NY: Society of Nuclear Medicine, 1988.
Xue LY, Noujaim AA, Sykes TR, et al. Role of transchelation in the uptake of Tc-99m antibodies in the liver and kidney.Q Nucl Med, in press.
Lind P, Smola MG, Lechner P, et al. The immunoscintigraphic use of99mTc labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary recurrent metastatic breast cancer.Int J Cancer 1991; 47: 865–869.
Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.J Nucl Med 1993; 34: 1067–1074.
Lamki LM, Buzdar AU, Singletary SE, et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.J Nucl Med 1991; 32: 1326–1332.
Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.Eur J Nucl Med 1995; 22: 645–651.
van Krooneburgh MJPG, Pauwels EJK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant disease.Nucl Med Commun 1988; 9: 919–930.
Reynolds JC, del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications.Nucl Med Biol 1989; 16: 121–125.
Janssen JAMJL, Blankestijn PJ, Docter R, et al. Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumor marker.Br Med J 1989; 298: 1511–1513.
Bischof Delaloye A, Delaloye B. Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?Eur J Nucl Med 1995; 22: 571–580.
Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast.J Am Coll Surg 1994; 178: 491–497.
Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses.Eur J Nucl Med 1994; 21: 432–436.
Lu G, Shih W-J, Huang H-Y, et al.99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging.Nucl Med Commun 1995; 16: 150–156.
Burak Z, Argon M, Memis A, et al. Evaluation of palpable breast masses with Tc-99m MIBI: a comparative study with mammography and ultrasonography.Nucl Med Commun 1994; 15: 604–612.
Lam WWW, Yang WT, Chan YL, et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography.Eur J Nucl Med 1996; 23: 498–503.
Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings and potential.AJR 1995; 164: 19–30.
Beany RP. Positron emission tomography in the study of human tumors.Semin Nucl Med 1984; 14: 324–341.
Minn H, Soini I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.Eur J Nucl Med 1989; 15: 61–66.
Wahl RL, Cody R, Hutchins G, Mudgett E. Positron-emission tomography scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy[18F]fluoro-d-glucose.N Engl J Med 1991; 324: 200.
Nieweg OE, Kim EE, Wong W-H et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.Cancer 1993; 71: 3920–3925.
Institute for Clinical PET Breast Cancer Task Force. Positron emission tomography — clinical application and economic implications of PET in the assessment of axillary lymph node in volvement in breast cancer: a retrospective study.Abstract from the 1994 ICP Meeting
Kotz D. Scintimammography: magic bullet or false promise?J Nucl Med 1995; 36: 15N-20N.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McQuarrie, S.A., MacLean, G.D., Boniface, G.R. et al. Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study. Eur J Nucl Med 24, 381–389 (1997). https://doi.org/10.1007/BF00881809
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00881809